Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

1,366 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Promoter methylation of the immune checkpoint receptor PD-1 (PDCD1) is an independent prognostic biomarker for biochemical recurrence-free survival in prostate cancer patients following radical prostatectomy.
Goltz D, Gevensleben H, Dietrich J, Ellinger J, Landsberg J, Kristiansen G, Dietrich D. Goltz D, et al. Among authors: dietrich j, dietrich d. Oncoimmunology. 2016 Sep 2;5(10):e1221555. doi: 10.1080/2162402X.2016.1221555. eCollection 2016. Oncoimmunology. 2016. PMID: 27853645 Free PMC article.
CDO1 promoter methylation is a biomarker for outcome prediction of anthracycline treated, estrogen receptor-positive, lymph node-positive breast cancer patients.
Dietrich D, Krispin M, Dietrich J, Fassbender A, Lewin J, Harbeck N, Schmitt M, Eppenberger-Castori S, Vuaroqueaux V, Spyratos F, Foekens JA, Lesche R, Martens JW. Dietrich D, et al. Among authors: dietrich j. BMC Cancer. 2010 Jun 1;10:247. doi: 10.1186/1471-2407-10-247. BMC Cancer. 2010. PMID: 20515469 Free PMC article.
CDO1 promoter methylation is associated with gene silencing and is a prognostic biomarker for biochemical recurrence-free survival in prostate cancer patients.
Meller S, Zipfel L, Gevensleben H, Dietrich J, Ellinger J, Majores M, Stein J, Sailer V, Jung M, Kristiansen G, Dietrich D. Meller S, et al. Among authors: dietrich j, dietrich d. Epigenetics. 2016 Dec;11(12):871-880. doi: 10.1080/15592294.2016.1241931. Epub 2016 Sep 30. Epigenetics. 2016. PMID: 27689475 Free PMC article.
PITX3 promoter methylation is a prognostic biomarker for biochemical recurrence-free survival in prostate cancer patients after radical prostatectomy.
Holmes EE, Goltz D, Sailer V, Jung M, Meller S, Uhl B, Dietrich J, Röhler M, Ellinger J, Kristiansen G, Dietrich D. Holmes EE, et al. Among authors: dietrich j, dietrich d. Clin Epigenetics. 2016 Sep 26;8:104. doi: 10.1186/s13148-016-0270-x. eCollection 2016. Clin Epigenetics. 2016. PMID: 27708722 Free PMC article.
1,366 results